A Study of Vitamin D Level in Type 2 Diabetic Patients before and after Treatment with Pioglitazone

Abstract

iabetes mellitus (DM) is one of the most common non-communicable diseases (NCDs) globally. It is the fourth or fifth leading cause of death in most high-income countries and there is substantial evidence that it is epidemic in many economically developing and newly industrialized countries. Diabetes is undoubtedly one of the most challenging health problems in the 21st century. Diabetes mellitus is frequently associated with vitamin D deficiency. In recent years, studies suggesting that vitamin D deficiency correlates with the severity and frequency of T2D and that vitamin D supplementation reduces the risk of developing T2D have been reported. Pioglitazonealone and in combination, has been shown to be effective at improving glycemic control, may delay or even prevent complications.

Our present study was conducted to evaluate vitamin D level in Type 2 diabetic patients before and after three month oftreatment with pioglitazone and assess any possible relationship in type 2 diabetic patients who are pioglitazone naïve. The study included 50 subjects, all females. The studied subjects divided into 2 groups: Group 1:20healthy female subjects as control. Group 2: 30female pioglitazone naïve diabetic patients. All individuals will be subjected to: • Full history takingandclinicalexamination • Biochemical tests • Fasting blood sugar, 2hours Post Prandial, and glycosylated hemoglobin (HbA1c). • Lipidprofile (total cholesterol, HDL, LDL, TG). • Kidney functiontests (serum creatinine, and BUN) • Serum 25-hydroxy vitamin D (by ELISA) before (basal)and after three months treatment with pioglitazone. All these data were statistically analyzed.